Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-01-13
2008-08-05
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C530S300000, C424S085100, C424S184100, C424S185100
Reexamination Certificate
active
07407936
ABSTRACT:
Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration within the nervous system. In another embodiment, treatment involves administering Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit neuronal degeneration in the nervous system, either the central nervous system or the peripheral nervous system. The activated T cells, which have been activated by the presence of Cop 1 or a Cop 1-related peptide or polypeptide, can be administered alone or in combination with Cop 1 or a Cop 1-related peptide or polypeptide.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 6214791 (2001-04-01), Arnon et al.
patent: 6342476 (2002-01-01), Konfino et al.
patent: 6844314 (2005-01-01), Eisenbach-Schwartz et al.
patent: WO 99/41247 (1999-08-01), None
Fridkis-Hareli et al. Binding of random copolymers of three amino acids to class II MHC molecules. Int Immunol 11(5):635-641.
Frielander, R.M. Apoptosis and Caspases in neurodegenaerative diseases. N Engl J Med 348: 1365-1375, 2000.
Vadja, F.J.E. Neuroprotection and neurodegenerative disease. J Clin Neurosci 9: 4-8, 2002.
Bakalash et al. Antigenic specificity of immunoprotective therapeutic vaccination for glaucoma. Invest Opthalmol Vis Sci 44(8): 3374-3381, 2003.
Angelov et al. Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 100: 4790-4795, 2003.
Kipnis et al. Therapeutic vaccination for closed head injury. J Neurotrauma 20(6): 559-569, 2003.
Bakalash et al. T-cell-based vaccination for morphological and functional neuroprotection in a rat model of chronically elevated intraocular pressure. J Mol Med 83(11): 904-916, 2005.
Schwartz et al. Protective autoimmunity and neuroprotection in inflammatory and noninflammatory neurodegenerative diseases. J Neurolog Sci 233: 163-166, 2005.
Aharoni et al, “Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis”,Proc Natl Acad Sci USA94:10821-10826 (1997).
Aharoni et al “Cop-1 specific suppressor cells inhibit experimental allergic encephalomyelitis induced by either mouse spinal cord homogenate or proteolipid protein peptide 139-151”,Neurology, Meeting Info.: 49thAnn. Meeting of the American Academy of Neurology, 48(3 (suppl. 2)):A422 (1997) (abstract).
Arnon et al, “New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis”,J Neurol243(4 Suppl 1):S8-13 (1996).
Bradbury et al, “NT-3, but not BDNF, prevents atrophy and death of axotomized spinal cord projection neurons”,Eur J Neurosci10(10):3058-3068 (1998 ).
Edwards et al, “Peptides as drugs”,QJ Med, 92(1):1-4 (1999).
Fiegen et al, “Recent advances in Huntington's disease: implications for experimental therapeutics”,Curr Opin Neurol15(4):483-489 (2002).
George et al, “Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels”,J Neurosci15(10):6445-6452 (1995).
Halliday et al, “Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms”,Clin Exp Pharmacol Physiol27(1-2):1-8 (2000).
Jackowski A, “Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer”,Br J Neurosurg9(3):303-317 (1995).
Kipnis et al, “T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies”,Proc Natl Acad Sci USA, 97:7446-7451 (2000).
Kipnis et al, “Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders”,Trends Mol Med8(7):319-323 (2002).
Miller et al, “Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation”,J Neuroimmunol92(1-2):113-121 (1998).
Pan et al, “Tumor necrosis factor-alpha: a neuromodulator in the CNS”,Neurosci Biobehav Rev21(5):603-613 (1997).
Petrovich et al, “Pentoxifylline suppression of TNF-alpha mediated axonal degeneration in the rabbit optic nerve”,Neurol Res19(5):551-554 (1997).
Plata-Salaman CR, “Epidermal growth factor and the nervous system”,Peptides12(3):653-663 (1991).
Schori et al, “Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma”,Proc Natl Acad Sci USA98(6):3398-34 3 (2001).
Schwartz M,Drug Develop Res50(3-4):223-225 (2000).
Steece-Collier et al, “Etiology of Parkinson's disease: Genetics and environment revisited”,Proc Natl Acad Sci USA99(22):13972-13974 (2002).
Teitelbaum et al, “Copolymer 1: from basic research to clinical application”,Cell Mol Life Sci53(1):24-28 (1997).
Teitelbaum et al, “Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1”,Proc Natl Acad Sci USA96(7):3842-3847 (1999).
Teva/Yeda/Hoechst Marion Roussel, “Copolymer-1, Glatriamer Acetate, Copaxone®: Agent for Multiple Sclerosis”,Drugs for the Future23(2) (1998).
Cohen Irun R
Eisenbach-Schwartz Michal
Kipnis Jonathan
Sela Michael
Yoles Eti
Allen Marianne P
Browdy and Neimark
Yeda Research and Development Co. Ltd.
LandOfFree
Use of copolymer 1 and related peptides and polypeptides and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of copolymer 1 and related peptides and polypeptides and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of copolymer 1 and related peptides and polypeptides and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4008082